Historique
Article de Périodique
Compared implementation of the long-acting buprenorphine treatment Buvidal in four European countries (2024)
Auteur(s) :
ROLLAND, B. ;
MATHESON, C. ;
KASKI, A. ;
KOSIM, M. ;
RONCERO, C. ;
VORSPAN, F.
Année
2024
Page(s) :
809-815
Langue(s) :
Anglais
Refs biblio. :
34
Domaine :
Autres substances / Other substances ; Drogues illicites / Illicit drugs
Thésaurus géographique
EUROPE
;
ROYAUME-UNI
;
FINLANDE
;
ESPAGNE
;
FRANCE
Thésaurus mots-clés
ETUDE QUALITATIVE
;
BUPRENORPHINE
;
TRAITEMENT DE MAINTENANCE
;
COMPARAISON
;
OPIOIDES
;
ACCES AUX SOINS
;
ENQUETE
;
PRODUIT ILLICITE
;
MARKETING
;
PRESCRIPTION MEDICALE
Autres mots-clés
Résumé :
BACKGROUND: Buvidal is the only depot buprenorphine currently available in Europe. Buvidal offers a new treatment paradigm, which may require some adjustment in the national regulatory frameworks for opioid agonist treatments (OATs), as well as the national care systems.
RESEARCH DESIGN AND METHODS: Data on the national dissemination of Buvidal, types of populations treated, and the national regulatory framework and care organization system through which Buvidal has been implemented were compared between the UK, Finland, Spain, and France, using a qualitative survey.
RESULTS: In 2022, the proportion of people on OAT who received Buvidal was 2.1% in the UK, 60-65% in Finland, 1% in Spain, and 0.3% in France. In both Finland and the UK, the cost of the medication is covered by the national health system, whereas, in Spain and France, Buvidal is accessible only in specialized centers, which must carry its cost. Other national features may explain the gaps in Buvidal use, including the baseline level of OAT coverage, which was high in both France and Spain.
CONCLUSIONS: Important national discrepancies are found regarding Buvidal dissemination among people on OAT. [Author's abstract]
RESEARCH DESIGN AND METHODS: Data on the national dissemination of Buvidal, types of populations treated, and the national regulatory framework and care organization system through which Buvidal has been implemented were compared between the UK, Finland, Spain, and France, using a qualitative survey.
RESULTS: In 2022, the proportion of people on OAT who received Buvidal was 2.1% in the UK, 60-65% in Finland, 1% in Spain, and 0.3% in France. In both Finland and the UK, the cost of the medication is covered by the national health system, whereas, in Spain and France, Buvidal is accessible only in specialized centers, which must carry its cost. Other national features may explain the gaps in Buvidal use, including the baseline level of OAT coverage, which was high in both France and Spain.
CONCLUSIONS: Important national discrepancies are found regarding Buvidal dissemination among people on OAT. [Author's abstract]
Affiliation :
Service Universitaire d'Addictologie de Lyon (SUAL), Hospices Civils de Lyon, CH Le Vinatier, Lyon, France
Faculty of Social Sciences, Colin Bell Building, University of Stirling, Stirling, UK
Kuopio Addiction Medicine Center, Päihdepalvelusäätiö, Kuopio, Finland
Camurus SAS, Paris, France
Assistance Publique-Hôpitaux de Paris, GHU Sorbonne Université, Hôpital Pitié-Salpêtrière, Consultations de médecine-Alcoologie PASS, Paris, France
Unidad de Psiquiatra, Facultad de Medicinia, Universidad de Salamanca & Instituto de Biomedicina (IBSAL), Spain; Universidad de Salamanca, C, Salamanca, Spain
Université Paris Cité, UFR de Médecine et INSERM UMRS 1144, Paris, France; Département de Psychiatrie et de Médecine Addictologique, Hôpital Fernand Widal, GHU NORD, Assistance Publique - Hôpitaux de, Paris, France
Faculty of Social Sciences, Colin Bell Building, University of Stirling, Stirling, UK
Kuopio Addiction Medicine Center, Päihdepalvelusäätiö, Kuopio, Finland
Camurus SAS, Paris, France
Assistance Publique-Hôpitaux de Paris, GHU Sorbonne Université, Hôpital Pitié-Salpêtrière, Consultations de médecine-Alcoologie PASS, Paris, France
Unidad de Psiquiatra, Facultad de Medicinia, Universidad de Salamanca & Instituto de Biomedicina (IBSAL), Spain; Universidad de Salamanca, C, Salamanca, Spain
Université Paris Cité, UFR de Médecine et INSERM UMRS 1144, Paris, France; Département de Psychiatrie et de Médecine Addictologique, Hôpital Fernand Widal, GHU NORD, Assistance Publique - Hôpitaux de, Paris, France